272nd ENMC International Workshop: 10 years of Progress - Revision of the ENMC 2013 Diagnostic Criteria for Inclusion Body Myositis and Clinical Trial Readiness. 16-18 June 2023, Hoofddorp, The Netherlands

Since the publication of the 2013 European Neuromuscular Center (ENMC) diagnostic criteria for Inclusion Body Myositis (IBM), several advances have been made regarding IBM epidemiology, pathogenesis, diagnostic tools, and clinical trial readiness. Novel diagnostic tools included muscle imaging techniques such as MRI and ultrasound, and serological testing for cytosolic 5’-nucleatidase-1A antibodies.The 272th ENMC workshop aimed to develop new diagnostic criteria and discuss clinical outcome measures and clinical trial readiness. The workshop started with patient representatives highlighting several understudied symptoms and the urge for a timely diagnosis. This was followed by presentations from IBM experts highlighting the new developments in the field.This report is composed of two parts, the first part providing new diagnostic criteria on which consensus was achieved. The second part focuses on the use of outcome measures in clinical practice and clinical trials, highlighting current limitations and outlining the goals for future studies.